



12

Bibliografía

1. Worldwide trends in the prevalence of asthma symptoms: phase III of the International Study of Asthma and Allergies in Childhood (ISAAC). *Thorax*. 2007 Sep;62(9):758-66
2. ECRHHS. The European Community Respiratory Health Survey II. *Eur Respir J*. 2002; 20: 1071-9
3. García-Marcos L, Quiros AB, Hernández GG et al. Stabilization of asthma prevalence and increase among school children (ISAAC phases I and III) in Spain. *Allergy* 2004 Dec;59(12): 1301-7
4. Martínez-Moratalla J, Almar E, Sunyer J, Ramos J, Pereira A, Payo F, Antó JM. Estudio Europeo del Asma. Identificación y tratamiento de individuos con criterios epidemiológicos de asma en adultos jóvenes de cinco áreas españolas. *Grupo Español del Estudio Europeo del Asma. Arch Bronconeumol* 1999; 35(5): 223-8
5. Martínez-Moragón E, Serra-Batlle J, De Diego A, Palop M, Casan P, Rubio-Terré C, Pellicer C. Coste económico del paciente asmático en España (estudio Asmacost). *Arch Bronconeumol*. 2009;45(10):481-486
6. Proceso Asistencial Integrado Asma en la edad pediátrica. Consejería de Salud. Junta de Andalucía. Sevilla, 2003.
7. Proceso Asistencial Integrado Asma del adulto. Consejería de Salud. Junta de Andalucía. Sevilla, 2004
8. Guía de diseño y mejora continua de procesos asistenciales integrados. Segunda edición. Sevilla. Consejería de Salud, 2009
9. Global Strategy for Asthma Management and Prevention (GINA 2011). www.ginasthma.org
10. BTS 2011. British Thoracic Society, Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. 2011. <http://www.sign.ac.uk/guidelines>
11. NAEPP-EP3 2007. National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the diagnosis and management of asthma. Bethesda: National Institutes of Health, National Heart, Lung, and Blood Institute, 2007. Disponible en: www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf
12. Guía española para el Manejo del Asma. 2009; 45, Extraordinario 7. Disponible en: www.archbronconeumol.org y www.gemasma.com
13. Bacharier LB, Boner A, Carlsen H et al. The European Pediatric Asthma Group. Diagnosis and treatment of asthma in childhood: a PRACTALL consensus report. *Allergy* 2008;63:5-34
14. Documento de consenso sobre asma bronquial en Andalucía. Neumosur, Samfyc, Semergen. 2009. Disponible en: <http://www.neumosur.net>
15. Castillo Laita JA, De Benito Fernández J, Escribano Montaner A, Fernández Benítez M, García de la Rubia S, Garde Garde J, et al. Consenso sobre tratamiento del asma en pediatría. *An Pediatr (Barc)*. 2007; 67(3): 253-73
16. http://www.juntadeandalucia.es/agenciadecalidadsanitaria/observatorioseguridadpaciente/gestor/sites/PortalObservatorio/es/menu/practicasSeguras/practicas_seguras_en_Cirugia_y_Anestesia. (Acceso 17 julio 2010)
17. Ley 41/2002. de 14 de noviembre, básica reguladora de la autonomía del paciente y de derechos y obligaciones en materia de información y documentación clínica
18. Castro-Rodríguez JA, Holberg CJ, Wright AL, Martinez FD. A clinical index to define risk of asthma in young children with recurrent wheezing. *Am J Respir Crit Care Med* 2000; 162:1403-1406
19. Guilbert TW, Morgan WJ, Zeiger RS, Bacharier LB, Boehmer SJ, Krawiec M, et al. Atopic characteristics of children with recurrent wheezing at high risk for the development of childhood asthma. *J Allergy Clin Immunol* 2004; 114:1282-1287
20. Moorhead S, Johnson M, Clasificación de Resultados Enfermeros (NOC), Cuarta Edición. Elsevier España. Barcelona 2009

21. Powell H, Gibson PG. Initial starting dose of inhaled corticosteroids in adults with asthma: a systematic review. *Thorax*. 2004; 59: 1041-5
22. Joos S, Miksch A, Szecsenyi J, Wieseler B, Grouven U, Kaiser T, et al. Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: a systematic review. *Thorax*. 2008; 63: 453-62
23. Ram FS, Cates CJ, Ducharme FM. Long acting beta-2 agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma. *Cochrane Database Syst Rev*. 2005; 25(1): CD003137. Update in: *Cochrane Database Syst Rev*. 2006; (4): CD003137
24. Humbert M, Beasley R, Ayres J, Slavin R, Hebert J, Bousquet J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. *Allergy* 2005;60(3):309-16
25. Powell H, Gibson PG. High dose versus low dose inhaled corticosteroid as initial starting dose for asthma in adults and children. *Cochrane Database of Systematic Reviews*. 2003; 4: CD004109. DOI: 10.1002/14651858.CD004109.pub2
26. Ducharme F, di Salvo F. Antileukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. *Cochrane Database of Systematic Reviews*. 2004; 1: CD002314. DOI: 10.1002/14651858.CD002314. pub2
27. De Blic J, Ogorodova L, Klink R, Sidorenko I, Valiulis A, Hofman J, et al. Salmeterol/fluticasone propionate vs. double dose fluticasone propionate on lung function and asthma control in children. *Pediatr Allergy Immunol* 2009;20(8):763-71
28. Gappa M, Zachgo W, Von Berg A, Kamin W, Stern-Strater C, Steinkamp G, et al. Add-on salmeterol compared to double dose fluticasone in pediatric asthma: A double-blind, randomized trial (VIAPAED). *Pediatr Pulmonol* 2009;44(11):1132-42
29. Morice AH, Peterson S, Beckman O, Kukova Z. Efficacy and safety of a new pressurised metered-dose inhaler formulation of budesonide/formoterol in children with asthma: a superiority and therapeutic equivalence study. *Pulm Pharmacol Ther* 2008;21(1):152-9
30. Lanier B, Bridges T, Kulus M, et al. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE mediated) asthma. *J Allergy Clin Immunol* 2009; 124:1210–1216
31. Rodrigo GJ, Neffen H, Castro-Rodríguez JA. Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma. *Chest* 2011; 139:28-35
32. Abramson MJ, Puy RM, Weiner JM. Allergen immunotherapy for asthma. *Cochrane Database Syst Rev*. 2003;CD001186
33. Gibson PG, Powell H, Coughlan J, Wilson AJ, Abramson M, Haywood Bauman A, et al. Educación para el autocuidado y examen médico regular para adultos con asma (Revisión Cochrane traducida). En: *La Biblioteca Cochrane Plus*, 2008 Número 1. Oxford: Update Software Ltd
34. Powell H, Gibson PG. Opciones para la educación sobre el autocuidado para los adultos con asma (Revisión Cochrane traducida). En: *La Biblioteca Cochrane Plus*, 2008, Número 1. Oxford: Update
35. Partridge MR. Patient education. En: O'Byrne P, Thomsen NC, editores. *Manual of asthma management*. WB Saunders. 1995. p. 378-92. 15
36. Orden 8 de julio de 2009, por la que se dictan instrucciones a los Centros del Sistema Sanitario Público de Andalucía, en relación al procedimiento de Consentimiento Informado. BOJA núm. 152 Página núm. 77. En www.juntadeandalucia.es
37. Pérez-Yarza EG, Badía X, Badiola C, Cobos N, Garde J, Ibero M, et al. On behalf of the CAN Investigator Group. Development and validation of a questionnaire to assess asthma control in pediatrics. *Pediatr Pulmonol*. 2009; 44: 54-63

38. Vega JM, Badia X, Badiola C, López-Viña A, Olaguibel JM, Picado C, et al. Covalair Investigator Group. Validation of the Spanish version of the Asthma Control Test (ACT). *J Asthma*. 2007; 44: 867-72
39. ALERTA 2008. Guía ALAT-SEPAR ALERTA. América Latina y España: Recomendaciones para la Prevención y el Tratamiento de la Exacerbación Asmática. Barcelona: Ed. Mayo 2008
40. Tapp S, Lasserson TJ, Rowe BH. Intervenciones educativas para adultos que asisten al servicio de urgencias por asma aguda. (Revisión Cochrane traducida) En: Biblioteca Cochrane plus 2008 n° 2. Oxford: Update software Ltd
41. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Interpretative strategies for lung function tests. *Eur Respir J*. 2005; 26(5): 948-68
42. Roca J, Sanchis J, Agustí-Vidal A, Segarra F, Navajas D, Rodríguez-Roisin R, Casan P, Sans S. Spirometric reference values from a Mediterranean population. *Bull Eur Physiopathol Respir* 1986; 22(3): 217-224
43. Quanjer PH, Borsboom GJ, Brunekreef B, Zach M, Forche G, Cotes JE et al. Spirometric reference values for white European children and adolescents: Polgar revisited. *Pediatr Pulmonol* 1995; 19(2): 135-142
44. Zapletal A, Chalupová J. Forced expiratory parameters in healthy preschool children (3-6 years of age). *Pediatr Pulmonol* 2003; 35(3): 200-207
45. Beydon N, Davis SD, Lombardi E, Allen JL, Arets H, Aurora P, et al. On behalf of the American Thoracic Society/European Respiratory Society Working Group on Infant and Young Children Pulmonary Function Testing. An Official American Thoracic Society/European Respiratory Society Statement: Pulmonary Function Testing in preschool Children. *Am J Respir Crit Care Med*. 2007; 175: 1304-45
46. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A et al; ATS/ERS Task Force. Standardisation of spirometry. *Eur Respir J* 2005; 26(2): 319-338
47. Casan P, Burgos F, Barberà JA, Giner J. Espirometría. En: Puente Maestu L. Manual SEPAR de Procedimientos. Procedimientos de evaluación de la función pulmonar I. Madrid: Luzan 5, 2002; 4-15. Disponible en www.separ.es
48. Reddel HK, Salome CM, Peat JK, Woolcock AJ. Which index of peak expiratory flow is most useful in the management of stable asthma? *Am J Respir Crit Care Med*. 1995; 151: 1320-5
49. ATS/ERS Recommendations for standardized procedures for online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide. 2005. *Am J Respir Crit Care Med*. 2005; 171: 912-30
50. Joos G.F., O'Connor B., on behalf of the Task Force. Indirect airway challenges. *Eur Respir J*. 2003; 21:1050-1068
51. Burgos Rincón F, Casan Clará P. Manual SEPAR de Procedimientos. Procedimientos de evaluación de la función pulmonar II. Madrid: Permanyer, 2004. Disponible en www.separ.es
52. Valencia A, Casan P, Perpiña M, Sebastián M.D. Normativa SEPAR: pruebas de provocación bronquial inespecífica (2002). Disponible en: www.separ.es
53. Asensio de la Cruz O, Cordón Martínez A, Elorz Lambarri J, Moreno Galdó A, Villa Asensi JR, Grupo de Técnicas de la Sociedad Española de Neumología Pediátrica. Estudio de la función pulmonar en el paciente colaborador. Parte II. *An Pediatr (Barc.)*. 2007; 66(5): 518-30
54. Ibero M, Escribano A, Sirvent J, Hernández G, Martínez A, Fernández M. Protocolos diagnósticos en asma bronquial (SENP, SEICAP). Protocolos diagnósticos y terapéuticos en pediatría
55. Navarro Merino M, Ledesma Benítez I, Pérez Pérez G, Romero Pérez MM. Test de esfuerzo. En *La Función Pulmonar en el Niño. Principios y Aplicaciones*. Editores E. González Pérez-Yarza,

- A. Aldasoro Ruiz, J. Korta Murua, J. Mintegui Aramburu y O. Sardón Prado. 2007. Ed. Ergon. Madrid
56. Crapo RO, Casaburi R, Coates AL, Enright PL, Hankinson JL, Irvin CG, et al. Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. *Am J Respir Crit Care Med.* 2000;161:309-29
57. Oppenheimer J, Nelson HS. Skin testing. *Ann Allergy Asthma Immunol* 2006; 96:S6-12
58. Heinzerling L, Frew AJ, Bindslev-Jensen C, Bonini S, Bousquet J, Bresciani M, et al. Standard skin prick testing and sensitization to inhalant allergens across Europe - a survey from GA2LEN network. *Allergy.* 2005; 60: 1287-300
59. Jahn-Schmid B, Harwanegg C, Hiller R, Bohle B, Ebner C, Scheiner O, Mueller MW. Allergen microarray: comparison of microarray using recombinant allergens with conventional diagnostic methods to detect allergen-specific serum immunoglobulin E. *Clin Exp Allergy.* 2003;33:1443-9
60. American Lung Association Asthma Clinical Research Centers, Peters SP, Anthonisen N, Castro M, Holbrook JT, Irvin CG, Smith LJ, Wise RA. Randomized comparison of strategies for reducing treatment in mild persistent asthma. *N Engl J Med* 2007; 356(20): 2027-39
61. Hawkins G, McMahon AD, Twaddle S, Wood SF, Ford I, Thomson NC. Stepping down inhaled corticosteroids in asthma: randomised controlled trial. *BMJ* 2003; 326(7399): 1115
62. Sharek PJ, Bergman DA. The effect of inhaled steroids on the linear growth of children with asthma: a meta-analysis. *Pediatrics* 2000;106(1): E8
63. Dunlop KA, Carson DJ, Steen HJ, McGovern V, McNaboe J, Shields MD. Monitoring growth in asthmatic children treated with high dose inhaled glucocorticoids does not predict adrenal suppression. *Arch Dis Child* 2004;89(8):713-6
64. Bernstein D AD. Evaluation of tests of hypothalamic-pituitary-adrenal axis function used to measure effects of inhaled corticosteroids. *Ann Allergy Asthma Immunol* 2007;98(2):118-27
65. Stein RT, Holberg CJ, Morgan WJ, Wright AL, Lombardi E, Taussig L, et al. Peak flow variability, methacholine responsiveness and atopy as markers for detecting different wheezing phenotypes in childhood. *Thorax.* 1997;52:946-52
66. Martínez FD. What have we learned from the Tucson Children's Respiratory Study? *Paediatr Respir Rev.* 2002;3:193-7
67. Morgan WJ, Stern DA, Sherrill DL, Guerra S, Holberg CJ, Guilbert TW, et al. Outcome of Asthma and Wheezing in the First 6 Years of Life: Follow-up through Adolescence. *Am J Respir Crit Care Med.* 2005;172:1253-8
68. Adams NP, Bestall JB, Malouf R, Lasserson TJ, Jones PW. Inhaled beclomethasone versus placebo for chronic asthma. *Cochrane Database Syst Rev.* 2005; (1): CD002738
69. Adams NP, Bestall JC, Lasserson TJ, Jones PW, Cates C. Fluticasone versus placebo for chronic asthma in adults and children. *Cochrane Database Syst Rev.* 2005; (4): CD003135
70. Bisgaard H, Zielen S, García-García ML, Johnston SL, Gilles L, Menten J, et al. Montelukast reduces asthma exacerbations in 2 to 5 year old children with intermittent asthma. *Am J Respir Crit Care Med.* 2005;171:315-22
71. Johnston NW, Mandhane PJ, Dai J, Duncan JM, Greene JM, Lambert K, Sears MR. Attenuation of the September epidemic of asthma exacerbations in children: a randomized, controlled trial of montelukast added to usual therapy. *Pediatrics* 2007;120:e702-12
72. De Benedictis FM, del Giudice MM, Forenza N, Decimo F, de Benedictis D, Capristo A. Lack of tolerance to the protective effect of montelukast in exercise-induced bronchoconstriction in children. *Eur Respir J.* 2006;28:291-5

73. Heuck C, Heickendorff L, Wolthers OD. A randomized controlled trial of short term growth and collagen turnover in asthmatics treated with inhaled formoterol and budesonide. *Arch Dis Child*. 2000;83:334-9
74. Bisgaard H, Le Roux P, Bjamer D, Dymek A, Vermeulen JH, Hultquist, C. Budesonide/Formoterol Maintenance Plus Reliever Therapy. A new strategy in pediatric asthma. *Chest*. 2006; 130: 1733-43
75. Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE. Metaanalysis: Effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. *Ann Intern Med*. 2006;144:904-12
76. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM. The Salmeterol Multicenter Asthma Research Trial: A comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. *Chest*. 2006;129:15-26
77. Salmeterol y formoterol: riesgo de reacciones asmáticas graves. *Inf Terapeutica SNS*. 2006;30:110-3
78. Ni Chroinin M, Greenstone IR, Danish A, Magdolinos H, Masse V, Zhang X, et al. Long-acting beta2- agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma. *Cochrane Database Syst Rev*. 2005; (4):CD005535
79. Rodrigo GJ, Plaza V, García-Marcos L, Castro Rodríguez JA. Safety of regular use of long-acting beta agonists as monotherapy or added to inhaled corticosteroids in asthma: a systematic review with meta-analysis. *Pulmonary Pharmacology and Therapeutics*. 2009; 22: 9-19
80. Ni Chroinin M, Greenstone IIG, Ducharme F. Addition of inhaled long acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naïve adults. *Cochrane Database of Systematic Reviews*. 2004; 4: CD005307. DOI: 10.1002/14651858.CD005307.pub2
81. Bousquet J, Van CP, Khaltaev N. Allergic rhinitis and its impact on asthma. *J Allergy Clin Immunol* 2001;108:S147–S334
82. Penagos M, Passalacqua G, Compalati E, Baena-Cagnani CE, Orozco S, Pedroza A, et al. Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. *Chest*. 2008; 133: 599-609
83. Olaguibel JM, Álvarez Puebla MJ. Efficacy of sublingual allergen vaccination for respiratory allergy in children. Conclusions from one metaanalysis. *J Investig Allergol Clin Immunol*. 2005; 15: 9-16
84. Durham SR, Walker SM, Varga EM, Jacobson MR, O'Brien F, Noble W et al. Long-term clinical efficacy of grass-pollen immunotherapy. *N Engl J med* 1999; 341:468-475
85. Eng PA, Borer-Reinhold M, Heinen IA, Gnehm HP. Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood. *Allergy* 2006; 61:198-201
86. Jacobsen L, Niggemann B, Dreborg S, Ferdousi HA, Halcken S, Høst A, et al. The PAT investigator group. Specific immunotherapy has long term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. *Allergy*. 2007; 62: 943-8
87. Des Roches A, Paradis L, Menardo JL et al. Immunotherapy prevents the onset of new sensitizations in children. *J Allergy Clin Immunol* 1997;99:450-453
88. Bruggenjurgen B, Reinhold T, Brehler R, Laake E, Wiese G, Machate U, Willich SN. Cost effectiveness of specific subcutaneous immunotherapy in patients with allergic rhinitis and allergic asthma. *Annals of Allergy, Asthma and Immunology* 2008; 101(3): 316-32
89. Bernstein DI, Wanner M, Borish L, Liss GM, Immunotherapy Committee, American Academy of Allergy, Asthma and Immunology. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001. *J Allergy Clin Immunol*. 2004; 113: 1129-36

90. Moreno C, Cuesta Herranz J, Fernández Tavora L, Álvarez Cuesta E. Immunotherapy safety: a prospective multi-centric monitoring study of biologically standardized therapeutic vaccines for allergic diseases. *Clin Exp Allergy*. 2004; 34: 527-31
91. Manejo práctico de la inmunoterapia. Disponible en: www.juntadeandalucia.es/servicioandaluzdesalud o en www.SEAIC.org
92. Canonica W, Bousquet J, Casale T, Lockey R, Baena-Cagnani C, Pawankar R et al. Sub-lingual Immunotherapy, World Allergy Organization Position paper 2009. *Allergy* 2009; 64 (suppl 91): 1-59
93. Nasser S, Vestenbaek U, Beriot-Mathiot A, Poulsen P B. Cost-effectiveness of specific immunotherapy with Grazax in allergic rhinitis co-existing with asthma. *Allergy* 2008; 63(12): 1624-1629
94. Gibson PG, Coughlan J, Wilson AJ, Abramson M, Bauman A, Hensley MJ, et al. Self-management education and regular practitioner review for adults with asthma. *Cochrane Database Syst Rev*. 2000; (2):CD001117. *Cochrane Database Syst Rev*. 2003; (1): CD001117
95. Gibson PG, Powell H. Written action plans for asthma: an evidence-based review of the key components. *Thorax*. 2004;59:94-9
96. Guevara JP, Wolf FM, Grum CM, Clark NM. Effects of educational interventions for self management of asthma in children and adolescents: Systematic review and meta-analysis. *BMJ*. 2003;326:1308-9
97. Wolf FM, Guevara JP, Grum CM, Clark NM, Cates CJ. Educational interventions for asthma in children. *Cochrane Database Syst Rev*. 2003; CD000326
98. Toelle BG, Ram FS. Written individualised management plans for asthma in children and adults. *Cochrane Database Syst Rev*. 2004;CD002171
99. Fuhlbrigge AL, Kitch BT, Paltiel AD, et al. FEV1 is associated with risk of asthma attacks in a pediatric population. *J Allergy Clin Immunol*. 2001; 107: 61-7
100. Petsky HL, Cates CJ, Li AM, Kynaston JA, Turner C, Chang AB. Tailored interventions based on exhaled nitric oxide versus clinical symptoms for asthma in children and adults. *Cochrane Database Syst Rev*. 2008(2): CD006340
101. Szeffler SJ, Mitchell H, Sorkness CA, Gergen PJ, O'Connor GT, Morgan WJ, et al. Management of asthma based on exhaled nitric oxide in addition to guideline-based treatment for innercity adolescents and young adults: a randomised controlled trial. *Lancet*. 2008; 372(9643): 1065-72
102. Petsky H, Kynaston J, Turner C, Li A, Cates C, Lasserson T, et al. Tailored interventions based on sputum eosinophils versus clinical symptoms for asthma in children and adults *Cochrane Database Syst Rev*. 2007(2): CD005603
103. Borgmeyer A, Gyr MP, Jamerson PA, Henry LD, Evaluation of the role of the pediatric nurse practitioner in a inpatient asthma program. *J Pediatr Health Care*. 2008; 22(5):273-81
104. Rodrigo C, Rodrigo G. Therapeutic response patterns to high and cumulative doses of salbutamol in acute severe asthma. *Chest*. 1998; 113: 593-8
105. Grunfeld A, Fitzgerald JM. Discharge considerations in acute asthma. *Can Respir J*. 1996; 3: 322-4
106. Cates CJ, Crilly JA, Rowe BH. Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma. *Cochrane Database of Systematic Reviews*. 2006; 2: CD000052. DOI: 10.1002/14651858.CD000052.pub2
107. Rowe BH, Spooner CH, Ducharme FM, Bota GW. Corticosteroids for preventing relapse following acute exacerbations of asthma. *Cochrane Database of Systematic Reviews*. 2007; 3: CD000195. DOI: 10.1002/14651858.CD000195

108. Manser R, Reid D, Abramson M. Corticosteroids for acute severe asthma in hospitalised patients. *Cochrane Database Syst Rev*. 2000. p. 2
109. Hasegawa T, Ishihara K, Takakura S, Fujii H, Nishimura T, Okazaki M, et al. Duration of systemic corticosteroids in the treatment of asthma exacerbation: a randomized study. *Intern Med*. 2000; 39(10): 794-7
110. Rodrigo GJ, Castro Rodríguez JA. Anticholinergics in the treatment of children and adults with acute asthma: a systematic review with meta-analysis *Thorax*. 2005; 60: 740-6
111. Rowe BH, Spooner C, Ducharme FM, Bretzlaff JA, Bota GW. Early emergency department treatment of acute asthma with systemic corticosteroids. *Cochrane Database of Systematic Reviews*. 2001; 1: CD002178. DOI: 10.1002/14651858.CD002178
112. Rodrigo GJ. Rapid effects of inhaled corticosteroids in acute asthma. An evidence-based evaluation. *Chest*. 2006; 130: 1301-11
113. Parameswaran K, Belda J, Rowe BH. Addition of intravenous aminophylline to beta2-agonists in adults with acute asthma. *Cochrane Database of Systematic Reviews*. 2000; 4: CD002742. DOI: 10.1002/14651858.CD002742
114. Rowe BH, Bretzlaff JA, Bourdon C, Bota GW, Camargo CA. Magnesium sulfate for treating exacerbations of acute asthma in the emergency department. *Cochrane Database of Systematic Reviews* 2000, Issue 1. Art. N°: CD001490
115. Ram FS, Wellington S, Rowe B, Wedzicha JA. Non-invasive positive pressure ventilation for treatment of respiratory failure due to severe acute exacerbations of asthma. *Cochrane Database of Systematic Reviews* 2005, Issue 3
116. Smith SR, Baty JD, Hodge D. Validation of the pulmonary score: An asthma severity score for children. *Acad Emerg Med*. 2002; 9: 99-104
117. Wright RO, Santucci KA, Jay GD, Steele DW. Evaluation of pre and posttreatment pulse oximetry in acute childhood asthma. *Acad Emerg Med*. 1997; 4(2): 114-7
118. Travers A, Jones AP, Kelly K, Barker SJ, Camargo CA, Rowe BH. Intravenous beta2-agonists for acute asthma in the emergency department. *Cochrane Database of Systematic Reviews* 2001. Issue 1. Art. CD002988. DOI: 10.1002/14651858.CD002988
119. Becker JM, Arora A, Scarfone RJ, Spector ND, Fontana-Penn ME, Gracely E, et al. Oral versus intravenous corticosteroids in children hospitalized with asthma. *J Allergy Clin Immunol*. 1999;103:586-90
120. López-Viña A, Agüero-Balbín R, Aller-Alvarez JL, Bazús-González T, Cosío BG, de Diego-Damiá A, Martínez-Moragón E, Pereira-Vega A, Plaza-Moral V, Rodríguez-Trigo G, Villa-Asensi JR; Area de Asma-SEPAR. Normativa para el asma de control difícil. *Arch Bronconeumol* 2005; 41(9): 513-23
121. Barnes PJ, Woolcock AJ. Difficult asthma. *Eur Respir J*. 1998; 12: 1209-18
122. Reddy RC. Severe asthma: approach and management. *Postgrad Med J* 2008; 84(989): 115-20
123. McKenzie SA, Bush A. Difficult asthma in children. *Thorax*. 2002;57:915-6
124. Navarro Merino M, Andrés A, Asensio O et al. Guía de diagnóstico y tratamiento del asma de difícil control en el niño. *An Pediatr (Barc)*. 2009;71(6):548-567 150
125. Martinez FD, Wright AL, Taussig LM, et al. Asthma and wheezing in the first six years of life. *N Engl J Med* 1995; 332: 133-138
126. Warner JO, Naspitz CK. Third Internacional Pediatric Consensus statement on the management of childhood asthma. International Pediatric Asthma Consensus Group. *Pediatr Pulmonol*. 1998; 25:1-17

127. Brand P, Baraldi E, Bisgaard H. ERS Task Force. Definition, assessment and treatment of wheezing disorders in preschool children: an evidence-based approach. *Eur Respir J* 2008; 32: 1096–1110
128. Martinez FD, Godfrey S. *Wheezing Disorders in the Preschool Child: Epidemiology, Diagnosis and Treatment*. London, Martin Dunitz, 2003
129. Nickel R, Kuling M, Forster J et al. Sensitization to hen's egg at the age of twelve months is predictive for allergic sensitization to common indoor and outdoor allergens at the age of three years. *J Allergy Clin Immunol* 1997; 99:613-617
130. Tariq SM, Matthews SM, Hakim E, Arshad S. Egg allergy in infancy predicts respiratory allergic disease by 4 years age. *Pediatr Allergy Immunol*. 2000; 11:162-7
131. Saglani S, Nicholson AG, Scallan M, Balfour-Lynn I, Rosenthal M, Payne DN et al. Investigation of young children with severe recurrent wheeze: any clinical benefit? *Eur Respir J*. 2006; 27:29-35
132. Saito J, Harris WT, Gelfond J, Noah TL, Leigh MW, Johnson R et al. Physiologic, bronchoscopic and bronchoalveolar lavage fluid findings in young children with recurrent wheeze and cough. *Pediatr Pulmonol*. 2006; 41:709-19
133. Hederos CA, Janson S, Andersson H, Hedlin G. Chest X-ray investigation in newly discovered asthma. *Pediatr Allergy Immunol*. 2004; 15:163-5
134. Guilbert T, Morgan W, Zeiger RS, Mauger DT, Boehmer SJ, Szefer SJ, et al. Long term inhaled corticosteroids in preschool children at high risk for asthma. *N Eng J Med*. 2006; 354:1985-97
135. McKean M, Ducharme f. Esteroides inhalados para las sibilancias virales episódicas de la infancia (Revisión Cochrane traducida). En: *La Biblioteca Cochrane Plus*, 2005 Número 1. Oxford: Update Software Ltd. Disponible en: <http://www.update-software.com> (Traducida de The Cochrane Library, 2005 Issue 1. Chichester, UK: John Wiley And Sons, Ltd.)
136. Bisgaard H, Hermansen MN, Loland L, Halkjaer LB, Buchvald F. Intermittent inhaled corticosteroids in infants with episodic wheezing. *N Eng J Med*. 2006; 354:1998-2005
137. Kadtis AG, Winnie G, Syrogiannopoulos GA. Anti-inflammatory pharmacotherapy for wheezing in preschool children. *Pediatr Pulmonol*. 2007; 42:407-20
138. Straub DA, Moeller A, Minocchieri S, Hamacher J, Sennhauser FH, Hall GL. The effect of montelukast on lung function and exhaled nitric oxide in infants with early childhood asthma. *Eur Respir J*. 2005; 25: 289-94
139. Van der Wouden JC, Tasche MJ, Bernsen RM, Uijen JH, de Jongste JC, Ducharme FM. Inhaled sodium cromoglycate for asthma in children. *Cochrane Database Syst Rev* 2003;CD002173
140. Everard ML, Bara A, Kurian M, Elliott TM, Ducharme F, Mayowe V. Anticholinergic drugs for wheeze in children under the age of two years. *Cochrane Database Syst Rev*. 2005 Jul 20;(3):CD001279
141. Ducharme F, Lemire C, Noya FJD, et al. preventive use of high-dose fluticasone for virus-induced wheezing in young children. *N Eng J Med* 2009; 360: 339-53
142. Jartti T, Lehtinen P, Vanto T, et al. Efficacy of prednisolone in children hospitalized for recurrent wheezing. *Ped Allergy Immunol* 2007; 18: 326-334
143. Murphy VE, Clifton VL, Gibson PG. Asthma exacerbations during pregnancy: incidence and association with adverse pregnancy outcomes. *Thorax*. 2006; 61(2): 169-76
144. Clifton V. Maternal asthma during pregnancy and fetal outcomes: potential mechanisms and possible solutions. *Curr Opin Allergy Clin Immunol*. 2006; 6(5): 307-11
145. Demissie K, Breckenridge MB, Rhoads GG. Infant and maternal outcomes in the pregnancies of asthmatic women. *Am J Respir Crit Care Med*. 1998; 158(4): 1091-5

146. Schatz M, Zeiger RS, Harden K. The safety of asthma and allergy medications during pregnancy. *J Allergy Clin Immunology*. 1997; 100: 301-6
147. Kallen B, Rydhstroem H, Aberg A. Congenital malformations after the use of inhaled budesonid in early pregnancy. *Obstet. Gynecol*. 1999; 93: 392-5
148. Rayburn WF, Atkinson BD, Gilbert K. Short term effects of inhaled albuterol on maternal and fetal circulations. *Am J Obstet Gynecolog*. 1994; 170: 770-3
149. Kogevinas M, Zock JP, Jarvis D, Kromhout H, Lillienberg L, Plana E, et al. Exposure to substances in the workplace and new-onset asthma: an international prospective population based study (ECRHS-II). *Lancet*. 2007; 28; 370: 336-41
150. Bernstein IL, Bernstein DI, Chan-Yeung M, Malo JL. Definitions and classification of asthma in the workplace. En: Bernstein IL, Chan-Yeung M, Malo JL, Bernstein DI, editores. *Asthma in the worplace*. 3ª ed. New York: Marcel Dekker. 2006. p. 1-8
151. Clayton T. Cowl. Occupational Asthma: Review of Assessment, Treatment, and Compensation. *Chest* 2011;139 674-681
152. Vandenas O, Cartier A, Malo JL. Occupational challenge test. En: Bernstein IL, Chan-Yeung M, Malo JL, Bernstein DI, editores. *Asthma in the workplace*. 3ª ed. New York: Marcel Dekker; 2006. p. 227-52
153. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 Update (in collaboration with the World Health Organization, GA2LEN* and AllerGen**). *Allergy*. 2008; 63(86): 8-160
154. Taramarcas P, Gibson PG. Intranasal corticosteroids for asthma control in people with coexisting asthma and rhinitis. *Cochrane Database Syst Rev*. 2003; (4): CD003570
155. Wilson DR, Lima MT, Durham SR. Sublingual immunotherapy for allergic rhinitis: systematic review and metaanalysis. *Allergy*. 2005; 60(1): 4-12
156. Calderón MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S. Allergen injection immunotherapy for seasonal allergic rhinitis. *Cochrane Database Syst Rev*. 2007: CD001936
157. Fokkens WJ, Lund VJ, Mullol J et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2012. *Rhinology* 2012; suppl 23: 1-298.
158. Nizankowska-Mogilnicka E, Bochenek G, Mastalerz L, Swierczyńska M, Picado C, Scadding G, et al. EAACI/GA2LEN guideline: aspirin provocation tests for diagnosis of aspirin hypersensitivity. *Allergy*. 2007;62: 1111-8
159. Casadevall J, Ventura PJ, Mullol J, Picado C. Intranasal challenge with aspirin in the diagnosis of aspirin intolerant asthma: Evaluation of nasal response by acoustic rhinometry. *Thorax*. 2000; 55: 921-49
160. Bulechek GM, Butcher HK, Mcloskey Dochterman J. Clasificación de intervenciones de enfermería (NIC). Quinta Edición. Elsevier Mosby. Barcelona. 2009